StockNews.com started coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the stock.
Trinity Biotech Price Performance
Trinity Biotech stock opened at $0.66 on Friday. The company has a market cap of $11.95 million, a PE ratio of -0.29 and a beta of 1.20. Trinity Biotech has a 12 month low of $0.63 and a 12 month high of $3.55. The company has a fifty day moving average price of $0.78 and a two-hundred day moving average price of $1.10.
Institutional Investors Weigh In On Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its stake in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 5.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 378,590 shares of the company’s stock after purchasing an additional 18,780 shares during the quarter. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 78.97% of the company’s stock.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Further Reading
- Five stocks we like better than Trinity Biotech
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 03/24 – 03/28
- The How And Why of Investing in Oil Stocks
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
- How to Use the MarketBeat Stock Screener
- 4 Healthcare Stocks With Massive Gains—and More to Come
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
